Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity –

Breakthrough: Two Rhythm Drugs Achieve Major Weight Loss in Rare Obesity Disease, Phase 3 Data Shows

New clinical data reveals impressive 19.8% BMI reduction in Phase 3 trial, while second drug shows promising results in Phase 2 study. See full efficacy data.

Consuming More Protein May Protect Patients Taking Anti-Obesity Drug From Muscle Loss

Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein intake may help prevent muscle loss in these patients, according to a small study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.